TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10626715
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg epidural morphine bolus with continuous epidural infusion of 4 mg morphine in 100 ml bupivacaine 0.125% (Group 1)
Study: 9174679
Drug: Ibuprofen effervescent
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen effervescent 400 mg
Study: 9174679
Drug: Ibuprofen effervescent
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen effervescent 800 mg
Study: 8645662
Drug: Ibuprofen tablets
Normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen tablets 400 mg
Study: 9174679
Drug: Ibuprofen tablets
Normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen tablets 800 mg
Study: 9174679
Drug: Ibuprofen effervescent
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen effervescent
Study: 23682858
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (60-min exercise class twice a week for 3 months)
Study: 19594035
Drug: Comprehensive rehabilitation
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive rehabilitation therapy including joint range of motion, activities of daily living, and restoring muscle strength starting from the 2nd day after surgery.
Study: 9661542
Drug: Warming intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming intravenous fluids at 42 degrees C
Study: 7854554
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy according to IOR‐OS/NEO 3 protocol
Study: 2574496
Drug: Atenolol (beta-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta-1 selective beta blocker)
Study: 237423
Drug: AH 8165
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH 8165 D (0.4-0.8 mg/kg body weight)
Study: 27117972
Drug: Lutonix drug-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutonix drug-coated balloon (DCB)
Study: 21932567
Drug: Beta-blocker metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker metoprolol tartrate
Study: 21932567
Drug: Standard antianginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antianginal therapy (including nitrates, anticoagulants, ACE inhibitors, and statins)
Study: 16169185
Drug: Intensive cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive cognitive-behavioral group treatment (CBGT)
Study: 8110914
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (mean serum level of 0.54 mEq/L)
Study: 8110914
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment and Placebo treatment
Study: 3606937
Drug: Dextropropoxyphene hydrochloride
Normalized name: Dextropropoxyphene hydrochloride
DrugBank: Dextropropoxyphene (DB00647)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextropropoxyphene hydrochloride 65 mg 8 hourly
Study: 3358901
Drug: Theophylline 125
Normalized name: theophylline 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 125 mg 8 hourly
Study: 3606937
Drug: Tolbutamide 500
Normalized name: tolbutamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolbutamide 500 mg i.v.
Study: 29866131
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT) with co-intervention exercise strategies (spine mobilizing and multifidus activating)
Study: 26254317
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment
Study: 19014835
Drug: Bevirimat 200
Normalized name: Bevirimat
DrugBank: Bevirimat (DB06581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevirimat 200 mg/d for 14 days
Study: 19014835
Drug: Atazanavir 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 400 mg/d on days 1 through 21 and bevirimat 200 mg/d on days 8 through 21
Study: 19014835
Drug: Atazanavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir monotherapy
Study: 16172184
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (1 mg) after 100 mg fluconazole
Study: 16172184
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (1 mg) after 200 mg fluconazole
Study: 16172184
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (1 mg) after 400 mg fluconazole
Study: 16172184
Drug: Intravenous alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfentanil (15 microg/kg) after 100 mg fluconazole
Study: 16172184
Drug: Intravenous alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfentanil (15 microg/kg) after 200 mg fluconazole
Study: 16172184
Drug: Intravenous alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfentanil (15 microg/kg) after 400 mg fluconazole
Study: 16172184
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (3 mg) after 100 mg fluconazole
Study: 16172184
Drug: Oral alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alfentanil (40 microg/kg) after 100 mg fluconazole
Study: 8685201
Drug: Tianeptine 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine 37.5 mg/day
Study: 6182817
Drug: Alloferin (alcuronium)
Normalized name: alcuronium
DrugBank: Alcuronium (DB13648)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alloferin (alcuronium) in burned patients, initial dose 23.75 mg (0.35 mg/kg)
Study: 6182817
Drug: Alloferin (alcuronium)
Normalized name: alcuronium
DrugBank: Alcuronium (DB13648)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alloferin (alcuronium) in control group, initial dose 15 mg (0.21 mg/kg)
Study: 31492121
Drug: Uitblinkers intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uitblinkers intervention (three sessions between an oral healthcare professional and parent)
Study: 29267221
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g whey protein (120 kcal)
Study: 29267221
Drug: 70 g
Normalized name: alcohol .70 g in 1 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 g whey protein (280 kcal)
Study: 24359313
Drug: SPN-804 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-804 1200 mg
Study: 24359313
Drug: SPN-804 2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-804 2400 mg
Study: 19318138
Drug: Mifepristone (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (plasma levels > or =1800 ng/ml)
Study: 15162890
Drug: Intravenous tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous tobramycin every 24 hours (10 mg/kg/dose for patients aged 6 months to < 9 years, 8 mg/kg/dose for 9 to < 12 years, 6 mg/kg/dose for ≥ 12 years)
Study: 15162890
Drug: Intravenous tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous tobramycin every 8 hours (2.5 mg/kg/dose)
Study: 15162890
Drug: Intravenous tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous tobramycin every 24 hours
Study: 8762219
Drug: Nicardipine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 50 mg slow release form (n = 57)
Study: 8762219
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg twice daily (n = 54)
Study: 1756043
Drug: Cefazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1 g single preoperative dose)
Study: 7141761
Drug: Propranolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (5 mg i.v.)
Study: 6124442
Drug: Labetalol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (20 mg i.v.)
Study: 6124442
Drug: Practolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (10 mg i.v.)
Study: 6124442
Drug: Labetalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (200 mg x 2, oral)
Study: 29561483
Drug: Mixed conventional/piezosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed conventional/piezosurgery preparation
Study: 29561483
Drug: Conventional preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional preparation with drills
Study: 25011352
Drug: HDM SLIT-tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM SLIT-tablet (maximum dose 32 DU in adults, 12 DU in children), administered once daily for 28 days
Study: 25011352
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered once daily for 28 days
Study: 25011352
Drug: HDM SLIT-tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM SLIT-tablet (maximum dose 12 DU in children), administered once daily for 28 days
Study: 20584227
Drug: Almotriptan 12.5
Normalized name: almotriptan 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 12.5 mg administered within 1 h of pain onset and when pain was mild (early + mild intervention group)
Study: 27829367
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg IV morphine
Study: 15616079
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.5% bupivacaine infiltrated subcutaneously
Study: 15616079
Drug: Inhaled 50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled 50% nitrous oxide in oxygen (Entonox) via a demand valve
Study: 11851182
Drug: Intracutaneous injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous injections of botulinum toxin (Botox) 2.5 U/0.1 ml, injected at 0.5 U/cm2 with 1 cm distance between injection points.
Study: 10468682
Drug: Famotidine 80
Normalized name: ibuprofen/famotidine 800 mg-26.6 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 80 mg b.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (FCM group; n = 60)
Study: 10468682
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg o.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (OCM group; n = 60)
Study: 10468682
Drug: Famotidine 80
Normalized name: ibuprofen/famotidine 800 mg-26.6 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 80 mg b.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (FCM group; n = 52)
Study: 10468682
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg o.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (OCM group; n = 57)
Study: 8589025
Drug: Cisplatin 8
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 8 mg/m2 on days 1-2, 8-9, 15-16, 22-23 and 5-fluorouracil 300 mg/m2 on days 3-7, 10-14, 17-21, 24-28 (35-day courses)
Study: 28973620
Drug: Genotype-guided warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided warfarin dosing
Study: 31259883
Drug: Traditional clinically
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional clinically guided warfarin dosing (Control)
Study: 26754176
Drug: Ceftriaxone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone administered at home
Study: 26754176
Drug: Flucloxacillin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucloxacillin administered in hospital
Study: 19470925
Drug: Paclitaxel (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (225 mg/m²) plus Carboplatin (AUC 6)
Study: 11351919
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care program implemented at CVS pharmacies
Study: 9783644
Drug: HMG reductase
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG reductase inhibitors
Study: 9783644
Drug: High-dose reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose reductase inhibitors
Study: 3048574
Drug: Busulfan maintenance
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan maintenance plus pulsed doses of cytarabine and lomustine
Study: 30086252
Drug: Standard dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dressing (povidone-iodine gauze and patch)
Study: 10763397
Drug: 900-mL 75-g
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 900-mL 75-g OGTT
Study: 10763397
Drug: 600-mL 75-g
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600-mL 75-g OGTT
Study: 10763397
Drug: 300-mL 75-g
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300-mL 75-g OGTT
Study: 9029414
Drug: Intravenous forskolin
Normalized name: Coleus forskohlii root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous forskolin (75 minute infusion)
Study: 3317344
Drug: Recombinant vaccine
Normalized name: CHO Cells Recombinant Vaccine
DrugBank: CHO Cells Recombinant Vaccine (DB15893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant vaccine
Study: 1450684
Drug: Plasma-derived vaccine
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived vaccine
Study: 29880546
Drug: Repetitive CD34+
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive CD34+ cell therapy (group A)
Study: 29880546
Drug: Single-dose CD34+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose CD34+ cell therapy (group B)
Study: 25363186
Drug: omega-3 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 (1000 mg/day)
Study: 15686271
Drug: Hyperbaric Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric Oxygen Therapy (HBO2), 120 treatments in blocks of 80 and 40 with a five-month break
Study: 11431192
Drug: Intraperitoneal cefepime,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal cefepime, 1 g once daily (group A)
Study: 11431192
Drug: Intravenous vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous vancomycin and netilmicin at conventional doses (group B)
Study: 29720238
Drug: 48 hours
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 hours of postoperative intravenously administered (IV) antibiotics
Study: 29720238
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of postoperative IV antibiotics
Study: 29720238
Drug: 48 hours
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 hours of postoperative IV antibiotics
Study: 18608311
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural group therapy for a 10-week period with relevant homework activities
Study: 12717068
Drug: Subdermal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdermal injection of both blue dye and radiotracer (Group A)
Study: 12717068
Drug: Periareolar injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periareolar injection of blue dye and subdermal injection of radiotracer (Group B)
Study: 1380024
Drug: Paracentesis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracentesis with Dextran 70 (6 g for each 1000 ml of ascites removed)
Study: 1380024
Drug: Paracentesis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracentesis with albumin (6 g for each 1000 ml of ascites)
Study: 6436832
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg sulfinpyrazone and 75 mg dipyridamole
Study: 6436832
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ASA and 75 mg dipyridamole
Study: 6436832
Drug: 330 mg
Normalized name: urea 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 330 mg ASA and 75 mg dipyridamole
Study: 31619187
Drug: Daprodustat 10
Normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Daprodustat 10 mg TIW
Study: 31619187
Drug: Daprodustat 15
Normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Daprodustat 15 mg TIW
Study: 31619187
Drug: Daprodustat 25
Normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Daprodustat 25 mg TIW
Study: 31619187
Drug: Daprodustat 30
Normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Daprodustat 30 mg TIW
Study: 24824481
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) as an adjunct to usual care (12-18 sessions)
Study: 24824481
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) as an adjunct to usual care
Study: 20022344
Drug: Cortisol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (160 mg/d for 4 days)
Study: 16226134
Drug: Prednisolone 50
Normalized name: prednisolone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 50 mg twice a day
Study: 12390100
Drug: Colostrum enema
Normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostrum enema (100 mL of 10% solution)
Study: 12390100
Drug: Placebo (albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (albumin solution)
Study: 10458123
Drug: Topical 0.2
Normalized name: coal tar topical 0.2% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.2 percent nifedipine gel every 12 hours for three weeks
Study: 10458123
Drug: Topical 1
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1 percent lidocaine and 1 percent hydrocortisone acetate gel
Study: 9282631
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of chloroquine (800 mg in three hours infusion)
Study: 2882775
Drug: Isoprenaline infusion
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline infusion (to heart rates of 100 to 110 beats min‐1)
Study: 2882775
Drug: Beta‐adrenoceptor blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta‐adrenoceptor blockers
Study: 26644956
Drug: Desvenlafaxine 100
Normalized name: desvenlafaxine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 100 mg/d
Study: 29103826
Drug: 64 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64 Gy (32 fractions) salvage radiation therapy (sRT)
Study: 29103826
Drug: 70 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 Gy (35 fractions) salvage radiation therapy (sRT)
Study: 27363506
Drug: Lacosamide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (200 mg b.i.d.)
Study: 19940014
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal soluble film (FBSF) at doses of 200-1200 microg
Study: 27651218
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg daily
Study: 27651218
Drug: Metformin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1.5 g daily
Study: 19127595
Drug: Entacapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (200 mg with each dose of levodopa)
Study: 11210394
Drug: Pantoprazole (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (0.12 to 1.15 mg/kg, i.v. for rats; 20 to 120 mg, i.v. and oral for humans)
Study: 9233868
Drug: Isoniazid (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (6 months of prophylactic treatment)
Study: 9233868
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 months of treatment)
Study: 8214650
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (50 mg/min for induction followed by 100 micrograms.kg‐1.min‐1 for maintenance)
Study: 8214650
Drug: Etomidate (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (8 mg/min and 20 micrograms.kg‐1.min‐1)
Study: 31688575
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg, once yearly for 2 years)
Study: 24411976
Drug: 400 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 µg/kg oral ivermectin
Study: 22244706
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of transdermal nicotine patch therapy
Study: 22244706
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of transdermal nicotine patch therapy
Study: 20150302
Drug: Mixed injection
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed injection of 0.2 units/kg lispro and 0.4 units/kg glargine
Study: 20150302
Drug: Separate injections
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injections of 0.2 units/kg lispro and 0.4 units/kg glargine
Study: 12486429
Drug: 5-mg dose
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-mg dose of rosuvastatin
Study: 12486429
Drug: 10-mg dose
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-mg dose of rosuvastatin
Study: 12486429
Drug: 10-mg dose
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-mg dose of atorvastatin
Study: 2674043
Drug: Nit removal
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nit removal system with formic acid cream rinse
Study: 2674043
Drug: Control section
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control section (no treatment)
Study: 29231476
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (sodium selenite, ibuprofen, vitamin C)